Timothy Juday

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. doi Factors associated with complete adherence to HIV combination antiretroviral therapy
    Timothy Juday
    Bristol Myers Squibb, Plainsboro, NJ, USA
    HIV Clin Trials 12:71-8. 2011
  2. pmc Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective
    Naoky Tsai
    John A Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
    Clinicoecon Outcomes Res 4:227-35. 2012
  3. pmc Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment
    Timothy Juday
    Research and Development, Bristol Myers Squibb Co, 777 Scudders Mill Road, Plainsboro, NJ 08536, USA
    J Gen Intern Med 26:239-44. 2011
  4. pmc A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States
    Timothy Juday
    Bristol Myers Squibb Research and Development, Plainsboro, NJ, USA
    AIDS Care 23:1154-62. 2011

Collaborators

Detail Information

Publications4

  1. doi Factors associated with complete adherence to HIV combination antiretroviral therapy
    Timothy Juday
    Bristol Myers Squibb, Plainsboro, NJ, USA
    HIV Clin Trials 12:71-8. 2011
    ..To assess factors associated with adherence, particularly pill burden, to combination antiretroviral therapy (cART) using multivariate models...
  2. pmc Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective
    Naoky Tsai
    John A Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
    Clinicoecon Outcomes Res 4:227-35. 2012
    ..Although entecavir has been shown to improve health outcomes in a cost-effective manner in mixed populations of CHB patients, the cost-effectiveness of entecavir has not been evaluated in CHB patients with decompensated cirrhosis...
  3. pmc Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment
    Timothy Juday
    Research and Development, Bristol Myers Squibb Co, 777 Scudders Mill Road, Plainsboro, NJ 08536, USA
    J Gen Intern Med 26:239-44. 2011
    ..This study aimed to assess adherence to treatment guideline-recommended monitoring of CHB patients not receiving antiviral treatment and to identify predictors of laboratory monitoring and subsequent initiation of antiviral therapy...
  4. pmc A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States
    Timothy Juday
    Bristol Myers Squibb Research and Development, Plainsboro, NJ, USA
    AIDS Care 23:1154-62. 2011
    ..39; p<0.001). HIV treatment persistence was longer with NNRTI-based regimens than PI-based regimens. The fixed-dose regimen of once-daily efavirenz/emtricitabine/tenofovir had the lowest risk of discontinuation...